Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Neoplasms of the CNS

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 181 articles:
HTML format



Single Articles


    June 2020
  1. OTT M, Kassab C, Marisetty A, Hashimoto Y, et al
    Radiation with STAT3 blockade triggers dendritic cell-T cell interactions in the glioma microenvironment and therapeutic efficacy.
    Clin Cancer Res. 2020 Jun 30. pii: 1078-0432.CCR-19-4092.
    PubMed     Abstract available


  2. RAO G, Latha K, Ott M, Sabbagh A, et al
    Anti-PD-1 induces M1 polarization in the glioma microenvironment and exerts therapeutic efficacy in the absence of CD8 cytotoxic T cells.
    Clin Cancer Res. 2020 Jun 18. pii: 1078-0432.CCR-19-4110.
    PubMed     Abstract available


  3. LADOMERSKY E, Zhai L, Lauing KL, Bell A, et al
    Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma.
    Clin Cancer Res. 2020 Jun 16. pii: 1078-0432.CCR-19-3874.
    PubMed     Abstract available


  4. KHASRAW M, Reardon DA, Weller M, Sampson JH, et al
    PD-1 inhibitors: Do they have a future in the treatment of glioblastoma?
    Clin Cancer Res. 2020 Jun 11. pii: 1078-0432.CCR-20-1135.
    PubMed     Abstract available


  5. INDRACCOLO S, De Salvo GL, Verza M, Caccese M, et al
    Phosphorylated Acetyl-CoA Carboxylase is associated with clinical benefit with Regorafenib in relapsed glioblastoma: REGOMA Trial Biomarker Analysis.
    Clin Cancer Res. 2020 Jun 9. pii: 1078-0432.CCR-19-4055.
    PubMed     Abstract available


    May 2020
  6. SCHEETZ L, Kadiyala P, Sun X, Son S, et al
    Synthetic high-density lipoprotein nanodiscs for personalized immunotherapy against gliomas.
    Clin Cancer Res. 2020 May 21. pii: 1078-0432.CCR-20-0341.
    PubMed     Abstract available


  7. KANE JR, Zhao J, Tsujiuchi T, Laffleur B, et al
    CD8(+) T-cell-mediated immunoediting influences genomic evolution and immune evasion in murine gliomas.
    Clin Cancer Res. 2020 May 19. pii: 1078-0432.CCR-19-3104.
    PubMed     Abstract available


  8. STRAGLIOTTO G, Pantalone MR, Rahbar A, Bartek J, et al
    Valganciclovir as add-on to standard therapy in glioblastoma patients.
    Clin Cancer Res. 2020 May 18. pii: 1078-0432.CCR-20-0369.
    PubMed     Abstract available


  9. BAGLEY SJ, Carpenter EL
    Plasma cfDNA in Glioblastoma-Response.
    Clin Cancer Res. 2020;26:2276.
    PubMed    


  10. TAKAYASU T, Esquenazi Y, Ballester LY
    Plasma cfDNA in Glioblastoma-Letter.
    Clin Cancer Res. 2020;26:2275.
    PubMed    


    April 2020
  11. EGUREN-SANTAMARIA I, Sanmamed MF, Goldberg SB, Kluger HM, et al
    PD-1/PD-L1 blockers in NSCLC brain metastases: challenging paradigms and clinical practice.
    Clin Cancer Res. 2020 Apr 30. pii: 1078-0432.CCR-20-0798.
    PubMed     Abstract available


  12. MENDEZ F, Kadiyala P, Nunez FJ, Carney S, et al
    Therapeutic efficacy of immune stimulatory thymidine kinase and fms-like tyrosine kinase 3 ligand (TK/Flt3L) gene therapy in a mouse model of high grade brainstem glioma.
    Clin Cancer Res. 2020 Apr 24. pii: 1078-0432.CCR-19-3714.
    PubMed     Abstract available


  13. LEE JH, Menzies AM, Carlino MS, McEvoy AC, et al
    Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors.
    Clin Cancer Res. 2020 Apr 22. pii: 1078-0432.CCR-19-3926.
    PubMed     Abstract available


  14. WEATHERS SP, Penas-Prado M, Pei BL, Ling X, et al
    Glioblastoma-mediated immune dysfunction limits CMV-specific T cells and therapeutic responses; results from a Phase I/II trial.
    Clin Cancer Res. 2020 Apr 16. pii: 1078-0432.CCR-20-0176.
    PubMed     Abstract available


  15. LAWLER SE, Chiocca EA, Cook CH
    Cytomegalovirus encephalopathy during brain tumor irradiation.
    Clin Cancer Res. 2020 Apr 10. pii: 1078-0432.CCR-20-0646.
    PubMed     Abstract available


  16. ELLINGSON BM, Yao J, Raymond C, Nathanson DA, et al
    Multi-parametric MR-PET imaging predicts pharmacokinetics and clinical response to GDC-0084 in patients with recurrent high-grade glioma.
    Clin Cancer Res. 2020 Apr 8. pii: 1078-0432.CCR-19-3817.
    PubMed     Abstract available


    March 2020
  17. MEEL MH, de Gooijer MC, Metselaar DS, Sewing ACP, et al
    Combined therapy of AXL and HDAC inhibition reverses mesenchymal transition in diffuse intrinsic pontine glioma.
    Clin Cancer Res. 2020 Mar 12. pii: 1078-0432.CCR-19-3538.
    PubMed     Abstract available


  18. OTANI Y, Yoo JY, Chao S, Liu J, et al
    Oncolytic HSV infected glioma cells activate NOTCH in adjacent tumor cells sensitizing tumors to gamma secretase inhibition.
    Clin Cancer Res. 2020 Mar 5. pii: 1078-0432.CCR-19-3420.
    PubMed     Abstract available


  19. KINSLOW CJ, Canoll P, Cheng SK, Wang TJC, et al
    Misclassification of Diffuse Gliomas-Letter.
    Clin Cancer Res. 2020;26:1198.
    PubMed    


    February 2020
  20. BEIG N, Bera K, Prasanna P, Antunes J, et al
    Radiogenomic-Based Survival Risk Stratification of Tumor Habitat on Gd-T1w MRI Is Associated with Biological Processes in Glioblastoma.
    Clin Cancer Res. 2020 Feb 20. pii: 1078-0432.CCR-19-2556.
    PubMed     Abstract available


  21. PIROVANO G, Jannetti SA, Carter LM, Sadique A, et al
    Targeted brain tumor radiotherapy using an Auger emitter.
    Clin Cancer Res. 2020 Feb 17. pii: 1078-0432.CCR-19-2440.
    PubMed     Abstract available


  22. DIRKS PB, Gilbert MR, Holland EC, Maher EA, et al
    Translating basic science discoveries into improved outcomes for glioblastoma.
    Clin Cancer Res. 2020 Feb 14. pii: 1078-0432.CCR-19-3924.
    PubMed     Abstract available


  23. WICK W, Wagener RJ
    Not yet another negative trial - ReACTing on recent glioblastoma trials!
    Clin Cancer Res. 2020 Feb 7. pii: 1078-0432.CCR-19-4032.
    PubMed     Abstract available


  24. REARDON DA, Desjardins A, Vredenburgh JJ, O'Rourke DM, et al
    Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.
    Clin Cancer Res. 2020 Feb 7. pii: 1078-0432.CCR-18-1140.
    PubMed     Abstract available


  25. ZHANG IY, Zhou H, Liu H, Zhang L, et al
    Local and Systemic Immune Dysregulation Alters Glioma Growth in Hyperglycemic Mice.
    Clin Cancer Res. 2020 Feb 4. pii: 1078-0432.CCR-19-2520.
    PubMed     Abstract available


  26. TANG B, Guo ZS, Bartlett DL, Yan DZ, et al
    Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma.
    Clin Cancer Res. 2020 Feb 4. pii: 1078-0432.CCR-18-3626.
    PubMed     Abstract available


  27. PASSARO C, Alayo Q, DeLaura I, McNulty J, et al
    Correction: Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy.
    Clin Cancer Res. 2020;26:758.
    PubMed    


    January 2020
  28. MOHME M, Maire CL, Geumann U, Schliffke S, et al
    Local intracerebral immunomodulation using interleukin-expressing mesenchymal stem cells in glioblastoma.
    Clin Cancer Res. 2020 Jan 27. pii: 1078-0432.CCR-19-0803.
    PubMed     Abstract available


  29. KUMTHEKAR P, Tang SC, Brenner AJ, Kesari S, et al
    ANG1005, a brain penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases.
    Clin Cancer Res. 2020 Jan 22. pii: 1078-0432.CCR-19-3258.
    PubMed     Abstract available


  30. GRAILLON T, Sanson M, Campello C, Idbaih A, et al
    Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
    Clin Cancer Res. 2020 Jan 22. pii: 1078-0432.CCR-19-2109.
    PubMed     Abstract available


  31. NASSIRI F, Taslimi S, Wang JZ, Badhiwala JH, et al
    Determining the optimal adjuvant therapy for improving survival in elderly patients with glioblastoma: a systematic review and meta-analysis.
    Clin Cancer Res. 2020 Jan 17. pii: 1078-0432.CCR-19-3359.
    PubMed     Abstract available


  32. POCHA K, Mock A, Rapp C, Dettling S, et al
    Surfactant expression defines an inflamed subtype of lung adenocarcinoma brain metastases that correlates with prolonged survival.
    Clin Cancer Res. 2020 Jan 17. pii: 1078-0432.CCR-19-2184.
    PubMed     Abstract available


  33. WEN PY, Cloughesy TF, Olivero AG, Morrissey KM, et al
    First-in-human Phase I study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma.
    Clin Cancer Res. 2020 Jan 14. pii: 1078-0432.CCR-19-2808.
    PubMed     Abstract available


  34. RODRIGUEZ GUTIERREZ D, Jones C, Varlet P, Mackay A, et al
    Radiological evaluation of newly diagnosed non-brainstem pediatric high-grade glioma in the HERBY phase II trial.
    Clin Cancer Res. 2020 Jan 10. pii: 1078-0432.CCR-19-3154.
    PubMed     Abstract available


  35. TU Y, Chen Z, Zhao P, Sun G, et al
    Smoothened promotes glioblastoma radiation resistance via activating USP3-mediated Claspin deubiquitination.
    Clin Cancer Res. 2020 Jan 3. pii: 1078-0432.CCR-19-1515.
    PubMed     Abstract available


  36. HIGUCHI F, Nagashima H, Ning J, Koerner MVA, et al
    Restoration of Temozolomide Sensitivity by Poly(ADP-Ribose) Polymerase inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
    Clin Cancer Res. 2020 Jan 3. pii: 1078-0432.CCR-19-2000.
    PubMed     Abstract available


    December 2019
  37. WORONIECKA KI, Rhodin KE, Dechant CA, Waibl Polania J, et al
    4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.
    Clin Cancer Res. 2019 Dec 23. pii: 1078-0432.CCR-19-1068.
    PubMed     Abstract available


  38. WU S, Gao F, Zheng S, Zhang C, et al
    EGFR amplification induces increased DNA damage response and renders selective sensitivity to Talazoparib (PARP inhibitor) in glioblastoma.
    Clin Cancer Res. 2019 Dec 18. pii: 1078-0432.CCR-19-2549.
    PubMed     Abstract available


  39. VAUBEL RA, Tian S, Remonde D, Schroeder MA, et al
    Genomic and phenotypic characterization of a broad panel of patient derived xenografts reflects the diversity of glioblastoma.
    Clin Cancer Res. 2019 Dec 18. pii: 1078-0432.CCR-19-0909.
    PubMed     Abstract available


  40. ZHANG DY, Dmello C, Chen L, Arrieta VA, et al
    Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations.
    Clin Cancer Res. 2019 Dec 12. pii: 1078-0432.CCR-19-2182.
    PubMed     Abstract available


  41. HARGRAVE DR, Bouffet E, Tabori U, Broniscer A, et al
    Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study.
    Clin Cancer Res. 2019 Dec 6. pii: 1078-0432.CCR-19-2177.
    PubMed     Abstract available


  42. CAMPAGNE O, Zhong B, Nair S, Lin T, et al
    Exposure-Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing.
    Clin Cancer Res. 2019 Dec 3. pii: 1078-0432.CCR-19-2685.
    PubMed     Abstract available


    October 2019
  43. BAGLEY S, Nabavizadeh SA, Mays J, Till JE, et al
    Clinical utility of plasma cell-free DNA in adult patients with newly diagnosed glioblastoma - a pilot prospective study.
    Clin Cancer Res. 2019 Oct 30. pii: 1078-0432.CCR-19-2533.
    PubMed     Abstract available


  44. PARADA CA, Osbun JW, Busald T, Karasozen Y, et al
    Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals Rb1 signaling as a Novel Mediator and Biomarker.
    Clin Cancer Res. 2019 Oct 15. pii: 1078-0432.CCR-18-0641.
    PubMed     Abstract available


    September 2019
  45. GERSTNER E, Emblem KE, Chang K, Vakulenko-Lagun B, et al
    Bevacizumab reduces permeability and concurrent temozolomide delivery in a subset of patients with recurrent glioblastoma.
    Clin Cancer Res. 2019 Sep 26. pii: 1078-0432.CCR-19-1739.
    PubMed     Abstract available


  46. VAN DER VOORT SR, Incekara F, Wijnenga MM, Kapsas G, et al
    Predicting the 1p/19q co-deletion status of presumed low grade glioma with an externally validated machine learning algorithm.
    Clin Cancer Res. 2019 Sep 23. pii: 1078-0432.CCR-19-1127.
    PubMed     Abstract available


  47. SHARIFI Z, Abdulkarim B, Meehan B, Rak J, et al
    Antitumor Activity of a Binary EGFR/DNA Targeting Strategy Overcomes Resistance of Glioblastoma Stem cells to Temozolomide.
    Clin Cancer Res. 2019 Sep 20. pii: 1078-0432.CCR-19-0955.
    PubMed     Abstract available


  48. THOMAS RP, Nagpal S, Iv M, Soltys SG, et al
    Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma.
    Clin Cancer Res. 2019 Sep 19. pii: 1078-0432.CCR-19-1421.
    PubMed     Abstract available


  49. PAPACHRISTODOULOU A, Silginer M, Weller M, Schneider H, et al
    Therapeutic targeting of TGF-beta ligands in glioblastoma using novel antisense oligonucleotides reduces the growth of experimental gliomas.
    Clin Cancer Res. 2019 Sep 17. pii: 1078-0432.CCR-17-3024.
    PubMed     Abstract available


  50. JUTHANI R, Madajewski B, Yoo B, Zhang L, et al
    Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model.
    Clin Cancer Res. 2019 Sep 12. pii: 1078-0432.CCR-19-1834.
    PubMed     Abstract available


  51. CHAUVIN C, Joalland N, Perroteau J, Jarry U, et al
    NKG2D controls natural reactivity of Vgamma9Vdelta2 T lymphocytes against mesenchymal glioblastoma cells.
    Clin Cancer Res. 2019 Sep 10. pii: 1078-0432.CCR-19-0375.
    PubMed     Abstract available


  52. JI J, Xu R, Ding K, Bao G, et al
    Long noncoding RNA SChLAP1 forms a growth promoting complex with HNRNPL in human glioblastoma through stabilization of ACTN4 and activation of NF-kappaB signaling.
    Clin Cancer Res. 2019 Sep 6. pii: 1078-0432.CCR-19-0747.
    PubMed     Abstract available


  53. WERBROUCK C, Evangelista CCS, Lobon-Iglesias MJ, Barret E, et al
    TP53 pathway alterations drive radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG).
    Clin Cancer Res. 2019 Sep 3. pii: 1078-0432.CCR-19-0126.
    PubMed     Abstract available


  54. LI J, Xue Y, Wenger A, Sun Y, et al
    Individual Assignment of Adult Diffuse Gliomas into the EM/PM Molecular Subtypes Using a TaqMan Low-Density Array.
    Clin Cancer Res. 2019 Sep 3. pii: 1078-0432.CCR-19-0299.
    PubMed     Abstract available


    August 2019
  55. BODEKER KL, Allen BG, Smith MC, Monga V, et al
    First-in-human phase 1 clinical trial of pharmacological ascorbate combined with radiation and temozolomide for newly diagnosed glioblastoma.
    Clin Cancer Res. 2019 Aug 19. pii: 1078-0432.CCR-19-0594.
    PubMed     Abstract available


    July 2019
  56. WEN PY, Reardon DA, Armstrong TS, Phuphanich S, et al
    A Randomized Double-Blind Placebo-Controlled Phase 2 Trial Of Dendritic Cell Vaccine ICT-107 In Newly Diagnosed Patients With Glioblastoma.
    Clin Cancer Res. 2019 Jul 18. pii: 1078-0432.CCR-19-0261.
    PubMed     Abstract available


  57. JUAREZ-CHAMBI RM, Kut C, Rico-Jimenez JJ, Chaichana KL, et al
    AI-Assisted In Situ Detection of Human Glioma Infiltration Using a Novel Computational Method for Optical Coherence Tomography.
    Clin Cancer Res. 2019 Jul 17. pii: 1078-0432.CCR-19-0854.
    PubMed     Abstract available


  58. YANG ZJ, Du F, Yuelling LW, Lee EH, et al
    Leukotriene synthesis is critical for medulloblastoma progression.
    Clin Cancer Res. 2019 Jul 12. pii: 1078-0432.CCR-18-3549.
    PubMed     Abstract available


  59. TIEN AC, Li J, Bao X, DeRogatis A, et al
    A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort.
    Clin Cancer Res. 2019 Jul 8. pii: 1078-0432.CCR-19-0133.
    PubMed     Abstract available


  60. JONSSON P, Lin AL, Young RJ, DiStefano NM, et al
    Genomic correlates of disease progression and treatment response in prospectively characterized gliomas.
    Clin Cancer Res. 2019 Jul 1. pii: 1078-0432.CCR-19-0032.
    PubMed     Abstract available


    June 2019
  61. RAPP C, Dettling S, Liu F, Ull AT, et al
    Cytotoxic T-cells and their activation status are independent prognostic markers in meningiomas.
    Clin Cancer Res. 2019 Jun 21. pii: 1078-0432.CCR-19-0389.
    PubMed     Abstract available


  62. KATAGI H, Louis N, Unruh D, Sasaki T, et al
    Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma.
    Clin Cancer Res. 2019 Jun 21. pii: 1078-0432.CCR-18-3890.
    PubMed     Abstract available


  63. FECCI PE, Champion CD, Hoj J, McKernan C, et al
    The Evolving Modern Management of Brain Metastasis.
    Clin Cancer Res. 2019 Jun 18. pii: 1078-0432.CCR-18-1624.
    PubMed     Abstract available


    May 2019
  64. SMITH SJ, Tyler B, Gould TWA, Veal GJ, et al
    Overall survival in malignant glioma is significantly prolonged by neurosurgical delivery of etoposide and temozolomide from a thermo-responsive biodegradable paste.
    Clin Cancer Res. 2019 May 21. pii: 1078-0432.CCR-18-3850.
    PubMed     Abstract available


    March 2019
  65. IDBAIH A, Canney M, Belin L, Desseaux C, et al
    Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma.
    Clin Cancer Res. 2019 Mar 19. pii: 1078-0432.CCR-18-3643.
    PubMed     Abstract available


  66. LI H, Li J, Chen L, Qi S, et al
    HERC3-mediated SMAD7 ubiquitination degradation promotes autophagy-induced EMT and chemoresistance in glioblastoma.
    Clin Cancer Res. 2019 Mar 12. pii: 1078-0432.CCR-18-3791.
    PubMed     Abstract available


  67. LAMANO JB, Lamano JB, Li YD, DiDomenico JD, et al
    Glioblastoma-Derived IL-6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.
    Clin Cancer Res. 2019 Mar 1. pii: 1078-0432.CCR-18-2402.
    PubMed     Abstract available


    February 2019
  68. TOMASZEWSKI W, Sanchez-Perez L, Gajewski TF, Sampson JH, et al
    Brain Tumor Micro-environment and Host State - Implications for Immunotherapy.
    Clin Cancer Res. 2019 Feb 25. pii: 1078-0432.CCR-18-1627.
    PubMed     Abstract available


  69. LASSMAN AB, Roberts-Rapp LA, Sokolova I, Song M, et al
    Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma.
    Clin Cancer Res. 2019 Feb 22. pii: 1078-0432.CCR-18-3034.
    PubMed     Abstract available


  70. HALL PE, Lewis R, Syed N, Shaffer R, et al
    A Phase I study of pegylated arginine deiminase (pegargiminase), cisplatin and pemetrexed in argininosuccinate synthetase 1-deficient recurrent high-grade glioma.
    Clin Cancer Res. 2019 Feb 22. pii: 1078-0432.CCR-18-3729.
    PubMed     Abstract available


  71. IPPEN FM, Alvarez-Breckenridge CA, Kuter BM, Fink AL, et al
    The dual PI3K/mTOR-pathway inhibitor GDC-0084 achieves antitumor activity in PIK3CA-mutant breast cancer brain metastases.
    Clin Cancer Res. 2019 Feb 22. pii: 1078-0432.CCR-18-3049.
    PubMed     Abstract available


  72. SIM HW, Nejad R, Zhang W, Nassiri F, et al
    Tissue 2-hydroxyglutarate as a biomarker for isocitrate dehydrogenase (IDH) mutations in gliomas.
    Clin Cancer Res. 2019 Feb 18. pii: 1078-0432.CCR-18-3205.
    PubMed     Abstract available


    January 2019
  73. INDIRA CHANDRAN V, Welinder C, Mansson AS, Offer S, et al
    Ultrasensitive immunoprofiling of plasma extracellular vesicles identifies syndecan-1 as a potential tool for minimally invasive diagnosis of glioma.
    Clin Cancer Res. 2019 Jan 24. pii: 1078-0432.CCR-18-2946.
    PubMed     Abstract available


  74. FINK MA, Paland H, Herzog S, Grube M, et al
    L-Carnitine Mediated Tumor Cell Protection and Poor Patient Survival Associated with OCTN2 Overexpression in Glioblastoma Multiforme.
    Clin Cancer Res. 2019 Jan 22. pii: 1078-0432.CCR-18-2380.
    PubMed     Abstract available


  75. YUN J, Hong MH, Kim SY, Park CW, et al
    YH25448, an irreversible EGFR-TKI with Potent Intracranial Activity in EGFR mutant non-small-cell lung cancer.
    Clin Cancer Res. 2019 Jan 22. pii: 1078-0432.CCR-18-2906.
    PubMed     Abstract available


  76. PARK J, Kwon M, Kim KH, Kim TS, et al
    Immune Checkpoint Inhibitor-Induced Reinvigoration of Tumor-Infiltrating CD8(+) T Cells is Determined by Their Differentiation Status in Glioblastoma.
    Clin Cancer Res. 2019 Jan 18. pii: 1078-0432.CCR-18-2564.
    PubMed     Abstract available


  77. MAJZNER RG, Theruvath JL, Nellan A, Heitzeneder S, et al
    CAR T cells targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
    Clin Cancer Res. 2019 Jan 17. pii: 1078-0432.CCR-18-0432.
    PubMed     Abstract available


  78. BERGEN ES, Berghoff AS, Medjedovic M, Rudas M, et al
    Continued endocrine therapy is associated with improved survival in patients with breast cancer brain metastases.
    Clin Cancer Res. 2019 Jan 15. pii: 1078-0432.CCR-18-1968.
    PubMed     Abstract available


  79. CHENG VWT, Soto MS, Khrapitchev AA, Perez-Balderas F, et al
    VCAM-1-targeted MRI Enables Detection of Brain Micrometastases from Different Primary Tumors.
    Clin Cancer Res. 2019;25:533-543.
    PubMed     Abstract available


  80. IORGULESCU JB, Torre M, Harary M, Smith TR, et al
    The Misclassification of Diffuse Gliomas: Rates and Outcomes.
    Clin Cancer Res. 2019 Jan 11. pii: 1078-0432.CCR-18-3101.
    PubMed     Abstract available


    December 2018
  81. HURVITZ SA, O'Shaughnessy J, Mason G, Yardley D, et al
    Central Nervous System Metastasis in Patients With HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival From SystHERs.
    Clin Cancer Res. 2018 Dec 28. pii: 1078-0432.CCR-18-2366.
    PubMed     Abstract available


  82. INDRACCOLO S, Lombardi G, Fassan M, Pasqualini L, et al
    Genetic, epigenetic and immunologic profiling of MMR-deficient relapsed glioblastoma.
    Clin Cancer Res. 2018 Dec 4. pii: 1078-0432.CCR-18-1892.
    PubMed     Abstract available


  83. HEGI ME, Genbrugge E, Gorlia T, Stupp R, et al
    MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide. A Pooled Analysis of Four Clinical Trials.
    Clin Cancer Res. 2018 Dec 4. pii: 1078-0432.CCR-18-3181.
    PubMed     Abstract available


    November 2018
  84. DAVIDSON TB, Lee AH, Hsu M, Sedighim S, et al
    Expression of PD-1 by T cells in malignant glioma patients reflects exhaustion and activation.
    Clin Cancer Res. 2018 Nov 29. pii: 1078-0432.CCR-18-1176.
    PubMed     Abstract available


  85. THULBORN KR, Lu A, Atkinson IC, Pauliah M, et al
    Residual Tumor Volume, Cell Volume Fraction and Tumor Cell Kill During Fractionated Chemoradiation Therapy of Human Glioblastoma using Quantitative Sodium MR imaging.
    Clin Cancer Res. 2018 Nov 28. pii: 1078-0432.CCR-18-2079.
    PubMed     Abstract available


  86. ROBBINS DJ, Rodriguez-Blanco J, Li B, Shen C, et al
    A CK1alpha activator penetrates the brain, and shows efficacy against drug-resistant metastatic medulloblastoma.
    Clin Cancer Res. 2018 Nov 28. pii: 1078-0432.CCR-18-1319.
    PubMed     Abstract available


  87. CHOI BD, Maus MV, June CH, Sampson JH, et al
    ----Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.
    Clin Cancer Res. 2018 Nov 16. pii: 1078-0432.CCR-18-1625.
    PubMed     Abstract available


  88. SPINO M, Kurz SC, Chiriboga L, Serrano J, et al
    Cell surface Notch ligand DLL3 is a therapeutic target in isocitrate dehydrogenase mutant glioma.
    Clin Cancer Res. 2018 Nov 5. pii: 1078-0432.CCR-18-2312.
    PubMed     Abstract available


    October 2018
  89. JIANG S, Eberhart CG, Lim M, Heo HY, et al
    Identifying Recurrent Malignant Glioma after Treatment Using Amide Proton Transfer-Weighted MR Imaging: A Validation Study with Image-Guided Stereotactic Biopsy.
    Clin Cancer Res. 2018 Oct 26. pii: 1078-0432.CCR-18-1233.
    PubMed     Abstract available


  90. PANDITHARATNA E, Kilburn LB, Aboian MS, Kambhampati M, et al
    Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy.
    Clin Cancer Res. 2018 Oct 15. pii: 1078-0432.CCR-18-1345.
    PubMed     Abstract available


  91. AGNIHOTRI S, Mansouri S, Burrell K, Li M, et al
    Ketoconazole and Posaconazole Selectively Target HK2 Expressing Glioblastoma Cells.
    Clin Cancer Res. 2018 Oct 15. pii: 1078-0432.CCR-18-1854.
    PubMed     Abstract available


  92. OSTI D, Del Bene M, Rappa G, Santos M, et al
    Clinical Significance of Extracellular Vesicles in Plasma from Glioblastoma Patients.
    Clin Cancer Res. 2018 Oct 4. pii: 1078-0432.CCR-18-1941.
    PubMed     Abstract available


  93. PASSARO C, Alayo Q, DeLaura I, McNulty JJ, et al
    Arming an oncolytic herpes simplex virus Type 1 with a single chain fragment variable antibody against PD-1 for experimental glioblastoma therapy.
    Clin Cancer Res. 2018 Oct 2. pii: 1078-0432.CCR-18-2311.
    PubMed     Abstract available


  94. BERBERICH A, Kessler T, Thome CM, Pusch S, et al
    Targeting resistance against the MDM2 inhibitor RG7388 in glioblastoma cells by the MEK inhibitor trametinib.
    Clin Cancer Res. 2018 Oct 1. pii: 1078-0432.CCR-18-1580.
    PubMed     Abstract available


    September 2018
  95. UNRUH D, Mirkov S, Wray B, Drumm M, et al
    Methylation-dependent Tissue Factor suppression contributes to the reduced malignancy of IDH1 mutant gliomas.
    Clin Cancer Res. 2018 Sep 28. pii: 1078-0432.CCR-18-1222.
    PubMed     Abstract available


  96. CRUICKSHANKS N, Zhang Y, Hine S, Gibert M, et al
    Discovery and therapeutic exploitation of mechanisms of resistance to MET inhibitors in glioblastoma.
    Clin Cancer Res. 2018 Sep 10. pii: 1078-0432.CCR-18-0926.
    PubMed     Abstract available


  97. WAHL DR, Lawrence TS
    No sugar added: A new strategy to inhibit glioblastoma receptor tyrosine kinases.
    Clin Cancer Res. 2018 Sep 4. pii: 1078-0432.CCR-18-2113.
    PubMed     Abstract available


    August 2018
  98. DAVARE MA, Henderson JJ, Agarwal A, Wagner JP, et al
    Rare but recurrent ROS1 fusions resulting from chromosome 6q22 microdeletions are targetable oncogenes in glioma.
    Clin Cancer Res. 2018 Aug 31. pii: 1078-0432.CCR-18-1052.
    PubMed     Abstract available


  99. BLAKELEY JO, Grossman SA, Chi AS, Mikkelsen T, et al
    Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.
    Clin Cancer Res. 2018 Aug 21. pii: 1078-0432.CCR-18-0110.
    PubMed     Abstract available


    July 2018
  100. MEEL MH, de Gooijer MC, Guillen Navarro M, Waranecki P, et al
    MELK inhibition in Diffuse Intrinsic Pontine Glioma.
    Clin Cancer Res. 2018 Jul 30. pii: 1078-0432.CCR-18-0924.
    PubMed     Abstract available


  101. ZINN PO, Singh SK, Kotrotsou A, Hassan I, et al
    A co-clinical radiogenomic validation study - Conserved magnetic resonance radiomic appearance of Periostin expressing Glioblastoma in patients and xenograft models.
    Clin Cancer Res. 2018 Jul 27. pii: 1078-0432.CCR-17-3420.
    PubMed     Abstract available


  102. ISHIDA CT, Zhang Y, Bianchetti E, Shu C, et al
    Metabolic Reprogramming by Dual AKT/ERK Inhibition Through Imipridones Elicits Unique Vulnerabilities in Glioblastoma.
    Clin Cancer Res. 2018 Jul 23. pii: 1078-0432.CCR-18-1040.
    PubMed     Abstract available


  103. ZHANG L, Sorensen M, Kristensen BW, Reifenberger G, et al
    The oncometabolite D-2-hydroxyglutarate is an intercellular mediator in IDH-mutant gliomas that inhibits both complement and T cells.
    Clin Cancer Res. 2018 Jul 13. pii: 1078-0432.CCR-17-3855.
    PubMed     Abstract available


  104. BARO M, Lopez Sambrooks C, Quijano A, Saltzman WM, et al
    Oligosaccharyltransferase inhibition Reduces Receptor Tyrosine Kinase Activation and Enhances Glioma Radiosensitivity.
    Clin Cancer Res. 2018 Jul 2. pii: 1078-0432.CCR-18-0792.
    PubMed     Abstract available


    June 2018
  105. LEE EQ, Duda DG, Muzikansky A, Gerstner E, et al
    Phase I and biomarker study of plerixafor and bevacizumab in recurrent high-grade glioma.
    Clin Cancer Res. 2018 Jun 25. pii: 1078-0432.CCR-18-1025.
    PubMed     Abstract available


  106. JURATLI TA, Stasik S, Zolal A, Schuster C, et al
    TERT promoter mutation detection in cell-free tumor-derived DNA in patients with IDH wild-type glioblastomas - a pilot prospective study.
    Clin Cancer Res. 2018 Jun 25. pii: 1078-0432.CCR-17-3717.
    PubMed     Abstract available


  107. DANKNER M, Lajoie M, Moldoveanu D, Nguyen TT, et al
    Dual MAPK inhibition is an effective therapeutic strategy for a subset of class II BRAF mutant melanoma.
    Clin Cancer Res. 2018 Jun 14. pii: 1078-0432.CCR-17-3384.
    PubMed     Abstract available


  108. BUERKI RA, Chheda ZS, Okada H
    Immunotherapy of Primary Brain Tumors: Facts and Hopes.
    Clin Cancer Res. 2018 Jun 5. pii: 1078-0432.CCR-17-2769.
    PubMed     Abstract available


    May 2018
  109. NODA M, Okayama H, Tachibana K, Sakamoto W, et al
    Glycosyltransferase gene expression identifies a poor prognostic colorectal cancer subtype associated with mismatch repair deficiency and incomplete glycan synthesis.
    Clin Cancer Res. 2018 May 29. pii: 1078-0432.CCR-17-3533.
    PubMed     Abstract available


  110. VOGELBAUM MA
    Targeted Therapies for Brain Tumors: Will They Ever Deliver?
    Clin Cancer Res. 2018 May 24. pii: 1078-0432.CCR-18-0855.
    PubMed     Abstract available


  111. SANAI N, Li J, Boerner J, Stark K, et al
    Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients.
    Clin Cancer Res. 2018 May 24. pii: 1078-0432.CCR-17-3348.
    PubMed     Abstract available


  112. LU CF, Hsu FT, Hsieh KL, Kao YJ, et al
    Machine Learning-Based Radiomics for Molecular Subtyping of Gliomas.
    Clin Cancer Res. 2018 May 22. pii: 1078-0432.CCR-17-3445.
    PubMed     Abstract available


  113. ZHANG Y, Ishida CT, Ishida W, Lo SL, et al
    Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and elicits Synthetic Lethality in Glioblastoma.
    Clin Cancer Res. 2018 May 15. pii: 1078-0432.CCR-18-0260.
    PubMed     Abstract available


    April 2018
  114. WILDES TJ, Grippin A, Dyson KA, Wummer BM, et al
    Cross-talk between T cells and hematopoietic stem cells during adoptive cellular therapy for malignant glioma.
    Clin Cancer Res. 2018 Apr 30. pii: 1078-0432.CCR-17-3061.
    PubMed     Abstract available


  115. GEDEON PC, Schaller TH, Chitneni SK, Choi BD, et al
    A rationally designed fully human EGFRvIII:CD3-targeted bispecific antibody redirects human T cells to treat patient-derived intracerebral malignant glioma.
    Clin Cancer Res. 2018 Apr 27. pii: 1078-0432.CCR-17-0126.
    PubMed     Abstract available


  116. KESARWANI P, Prabhu A, Kant S, Kumar P, et al
    Tryptophan metabolism contributes to radiation-induced immune checkpoint reactivation in glioblastoma.
    Clin Cancer Res. 2018 Apr 24. pii: 1078-0432.CCR-18-0041.
    PubMed     Abstract available


  117. JACKSON CM, Lim M
    Immunotherapy for glioblastoma: playing chess, not checkers.
    Clin Cancer Res. 2018 Apr 24. pii: 1078-0432.CCR-18-0491.
    PubMed     Abstract available


  118. MARTINEZ-RICARTE F, Mayor R, Martinez-Saez E, Rubio-Perez C, et al
    Molecular diagnosis of diffuse gliomas through sequencing of cell-free circulating tumour DNA from cerebrospinal fluid.
    Clin Cancer Res. 2018 Apr 3. pii: 1078-0432.CCR-17-3800.
    PubMed     Abstract available


    March 2018
  119. SAHA D, Wakimoto H, Peters CW, Antoszczyk SJ, et al
    Combinatorial effects of VEGFR kinase inhibitor axitinib and oncolytic virotherapy in mouse and human glioblastoma stem-like cell models.
    Clin Cancer Res. 2018 Mar 29. pii: 1078-0432.CCR-17-1717.
    PubMed     Abstract available


  120. WORONIECKA KI, Rhodin KE, Chongsathidkiet P, Keith KA, et al
    T-Cell Dysfunction in Glioblastoma: Applying a New Framework.
    Clin Cancer Res. 2018 Mar 28. pii: 1078-0432.CCR-18-0047.
    PubMed     Abstract available


  121. DETTLING S, Stamova S, Warta R, Schnolzer M, et al
    Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-cell Targets in Human IDH-Mutant Glioma.
    Clin Cancer Res. 2018 Mar 21. pii: 1078-0432.CCR-17-1839.
    PubMed     Abstract available


  122. NAKASHIMA H, Nguyen T, Kasai K, Passaro C, et al
    Toxicity and efficacy of a novel GADD34-expressing oncolytic HSV-1 for the treatment of experimental glioblastoma.
    Clin Cancer Res. 2018 Mar 6. pii: 1078-0432.CCR-17-2954.
    PubMed     Abstract available


  123. LADOMERSKY E, Zhai L, Lenzen A, Lauing KL, et al
    IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma.
    Clin Cancer Res. 2018 Mar 2. pii: 1078-0432.CCR-17-3573.
    PubMed     Abstract available


    February 2018
  124. NISHIYAMA A, Yamada T, Kita K, Wang R, et al
    Foretinib overcomes entrectinib resistance associated with the NTRK1 G667C mutation in NTRK1 fusion-positive tumor cells in a brain metastasis model.
    Clin Cancer Res. 2018 Feb 20. pii: 1078-0432.CCR-17-1623.
    PubMed     Abstract available


  125. LI XN, Kogiso M, Qi L, Braun FK, et al
    Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX models.
    Clin Cancer Res. 2018 Feb 20. pii: 1078-0432.CCR-17-2256.
    PubMed     Abstract available


  126. MOHME M, Schliffke S, Maire CL, Runger A, et al
    Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes.
    Clin Cancer Res. 2018 Feb 14. pii: 1078-0432.CCR-17-2617.
    PubMed     Abstract available


  127. HOLLON TC, Orringer DA
    Shedding light on IDH1 mutation in gliomas.
    Clin Cancer Res. 2018 Feb 13. pii: 1078-0432.CCR-18-0011.
    PubMed     Abstract available


  128. WORONIECKA K, Chongsathidkiet P, Rhodin KE, Kemeny HR, et al
    T Cell Exhaustion Signatures Vary with Tumor Type and are Severe in Glioblastoma.
    Clin Cancer Res. 2018 Feb 7. pii: 1078-0432.CCR-17-1846.
    PubMed     Abstract available


  129. GORDON RE, Zhang L, Peri S, Kuo YM, et al
    Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma.
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-2923.
    PubMed     Abstract available


  130. KABRAJI S, Ni J, Lin N, Xie S, et al
    Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain?
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-3351.
    PubMed     Abstract available


    January 2018
  131. GOMEZ S, Garrido-Garcia A, Garcia-Gerique L, Lemos I, et al
    A novel method for rapid molecular subgrouping of medulloblastoma.
    Clin Cancer Res. 2018 Jan 19. pii: 1078-0432.CCR-17-2243.
    PubMed     Abstract available


  132. NIMMERVOLL B, Boulos N, Bianski BM, Dapper J, et al
    Establishing A Preclinical Multidisciplinary Board for Brain Tumors.
    Clin Cancer Res. 2018 Jan 4. pii: 1078-0432.CCR-17-2168.
    PubMed     Abstract available


    December 2017
  133. PAL J, Patil V, Kumar A, Kaur K, et al
    Loss-of-function mutations in Calcitonin receptor (CALCR) identify highly aggressive glioblastoma with poor outcome.
    Clin Cancer Res. 2017 Dec 20. pii: 1078-0432.CCR-17-1901.
    PubMed     Abstract available


  134. UCKERMANN O, Juratli TA, Galli R, Conde M, et al
    Optical analysis of glioma: Fourier-transform infrared spectroscopy reveals the IDH1 mutation status.
    Clin Cancer Res. 2017 Dec 19. pii: 1078-0432.CCR-17-1795.
    PubMed     Abstract available


  135. SU YT, Chen R, Wang H, Song H, et al
    Novel Targeting of Transcription and Metabolism in Glioblastoma.
    Clin Cancer Res. 2017 Dec 18. pii: 1078-0432.CCR-17-2032.
    PubMed     Abstract available


  136. JIN X, Jin X, Kim LJY, Dixit D, et al
    Inhibition of ID1-BMPR2 intrinsic signaling sensitizes glioma stem cells to differentiation therapy.
    Clin Cancer Res. 2017 Dec 5. pii: 1078-0432.CCR-17-1529.
    PubMed     Abstract available


    November 2017
  137. CHANG K, Bai HX, Zhou H, Su C, et al
    Residual Convolutional Neural Network for Determination of IDH Status in Low- and High-grade Gliomas from MR Imaging.
    Clin Cancer Res. 2017 Nov 22. pii: clincanres.2236.2017.
    PubMed     Abstract available


  138. WEISS T, Schneider H, Silginer M, Steinle A, et al
    NKG2D-dependent anti-tumor effects of chemotherapy and radiotherapy against glioblastoma.
    Clin Cancer Res. 2017 Nov 21. pii: clincanres.1766.2017.
    PubMed     Abstract available


  139. MIGLIORINI D, Dietrich PY, Stupp R, Linette GP, et al
    CAR-T cell Therapies in Glioblastoma: a first look.
    Clin Cancer Res. 2017 Nov 20. pii: clincanres.2871.2017.
    PubMed     Abstract available


  140. NANDHU MS, Behera P, Bhaskaran V, Longo SL, et al
    Development of a function-blocking antibody against fibulin-3 as targeted reagent for glioblastoma.
    Clin Cancer Res. 2017 Nov 16. pii: clincanres.1628.2017.
    PubMed     Abstract available


  141. CHEN Q, Cai J, Wang Q, Wang Y, et al
    Long non-coding RNA NEAT1, regulated by the EGFR pathway, contributes to glioblastoma progression through the WNT/beta-Catenin pathway by scaffolding EZH2.
    Clin Cancer Res. 2017 Nov 14. pii: clincanres.0605.2017.
    PubMed     Abstract available


  142. WICK W, Kessler T
    Drug repositioning meets precision in glioblastoma.
    Clin Cancer Res. 2017 Nov 13. pii: clincanres.2989.2017.
    PubMed     Abstract available


    October 2017
  143. BYRON SA, Tran NL, Halperin RF, Phillips JJ, et al
    Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma.
    Clin Cancer Res. 2017 Oct 26. pii: clincanres.0963.2017.
    PubMed     Abstract available


  144. PRICEMAN SJ, Tilakawardane D, Jeang B, Murad JP, et al
    Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.2041.2017.
    PubMed     Abstract available


  145. FAN Y, Zhu X, Xu Y, Lu X, et al
    Cell-cycle and DNA-damage response pathway is involved in leptomeningeal metastasis of non-small cell lung cancer.
    Clin Cancer Res. 2017 Oct 13. pii: clincanres.1582.2017.
    PubMed     Abstract available


  146. ACERBI F, Broggi M, Schebesch KM, Hohne J, et al
    Fluorescein-guided surgery for resection of high-grade gliomas: A multicentric prospective phase II study (FLUOGLIO).
    Clin Cancer Res. 2017 Oct 10. pii: clincanres.1184.2017.
    PubMed     Abstract available


    September 2017
  147. AVRIL T, Etcheverry A, Pineau R, Obacz J, et al
    CD90 expression controls migration and predicts dasatinib response in glioblastoma.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.1549.2017.
    PubMed     Abstract available


  148. LI J, Wu J, Bao X, Honea N, et al
    Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients using an IVIVE-PBPK Modeling Approach.
    Clin Cancer Res. 2017 Sep 19. pii: clincanres.0983.2017.
    PubMed     Abstract available


  149. MULLER-GREVEN GM, Carlin C, Burgett ME, Ahluwalia MS, et al
    Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival.
    Clin Cancer Res. 2017 Sep 14. pii: clincanres.0249.2017.
    PubMed     Abstract available


  150. CHOI SH, Stuckey DW, Pignatta S, Reinshagen C, et al
    Tumor resection boosts therapeutic efficacy of encapsulated stem cells expressing a highly secretable variant of interferon-beta in glioblastomas.
    Clin Cancer Res. 2017 Sep 14. pii: clincanres.0077.2017.
    PubMed     Abstract available


    August 2017
  151. FELSBERG J, Hentschel B, Kaulich K, Gramatzki D, et al
    Prognostic role of Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified primary and recurrent glioblastomas.
    Clin Cancer Res. 2017 Aug 29. pii: clincanres.0890.2017.
    PubMed     Abstract available


  152. ALEXANDER BM, Ba S, Berger MS, Berry DA, et al
    Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.
    Clin Cancer Res. 2017 Aug 16. pii: clincanres.0764.2017.
    PubMed     Abstract available


  153. OLMEZ I, Brenneman B, Xiao A, Serbulea V, et al
    Combined CDK4/6 and mTOR inhibition is synergistic against glioblastoma via multiple mechanisms.
    Clin Cancer Res. 2017 Aug 16. pii: clincanres.0803.2017.
    PubMed     Abstract available


  154. WANG G, Shen J, Sun J, Jiang Z, et al
    Cyclophilin A Maintains Glioma-Initiating Cell Stemness by Regulating Wnt/beta-catenin Signaling.
    Clin Cancer Res. 2017 Aug 8. pii: clincanres.0774.2017.
    PubMed     Abstract available


    July 2017
  155. ZHANG CB, Cheng W, Ren X, Wang Z, et al
    Tumor Purity As an Underlying Key Factor in Glioma.
    Clin Cancer Res. 2017 Jul 28. pii: clincanres.2598.2016.
    PubMed     Abstract available


  156. ZHAI L, Ladomersky E, Lauing KL, Wu M, et al
    Infiltrating T cells increase IDO1 expression in glioblastoma and contribute to decreased patient survival.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.0120.2017.
    PubMed     Abstract available


  157. PATEL SH, Poisson LM, Brat DJ, Zhou Y, et al
    T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower Grade Gliomas: A TCGA/TCIA Project.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.0560.2017.
    PubMed     Abstract available


  158. OIZEL K, Chauvin C, Oliver L, Gratas C, et al
    Efficient mitochondrial glutamine targeting prevails over glioblastoma metabolic plasticity.
    Clin Cancer Res. 2017 Jul 18. pii: clincanres.3102.2016.
    PubMed     Abstract available


  159. FAN QW, Nicolaides TP, Weiss WA
    Inhibiting 4EBP1 in glioblastoma.
    Clin Cancer Res. 2017 Jul 10. pii: clincanres.0042.2017.
    PubMed     Abstract available


  160. CANELLA A, Welker AM, Yoo JY, Xu J, et al
    Efficacy of Onalespib a Long-acting Second Generation HSP90 Inhibitor as a Single Agent and in Combination with Temozolomide Against Malignant Gliomas.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.3151.2016.
    PubMed     Abstract available


    June 2017
  161. ELLINGSON BM, Gerstner E, Smits M, Huang RY, et al
    Diffusion MRI phenotypes predict overall survival benefitfrom anti-VEGF monotherapy in recurrent glioblastoma:Converging evidence from phase II trials.
    Clin Cancer Res. 2017 Jun 27. pii: clincanres.2844.2016.
    PubMed     Abstract available


  162. COOK SANGAR ML, Genovesi LA, Nakamoto MW, Davis MJ, et al
    Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models.
    Clin Cancer Res. 2017 Jun 21. pii: clincanres.2943.2016.
    PubMed     Abstract available


    May 2017
  163. GEOERGER B, Bourdeaut F, DuBois SG, Fischer M, et al
    A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.
    Clin Cancer Res. 2017;23:2433-2441.
    PubMed     Abstract available


  164. SLANEY CY, von Scheidt B, Davenport AJ, Beavis PA, et al
    Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.
    Clin Cancer Res. 2017;23:2478-2490.
    PubMed     Abstract available


    April 2017
  165. BAKAS S, Akbari H, Pisapia J, Martinez-Lage M, et al
    In vivo detection of EGFRvIII in glioblastoma via perfusion magnetic resonance imaging signature consistent with deep peritumoral infiltration: the phi index.
    Clin Cancer Res. 2017 Apr 20. pii: clincanres.1871.2016.
    PubMed     Abstract available



  166. Correction: Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1-Mediated Lipogenesis.
    Clin Cancer Res. 2017;23:2127.
    PubMed    


  167. BATICH KA, Reap EA, Archer GE, Sanchez-Perez L, et al
    Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.
    Clin Cancer Res. 2017;23:1898-1909.
    PubMed     Abstract available


  168. BI WL, Horowitz P, Greenwald NF, Abedalthagafi M, et al
    Landscape of Genomic Alterations in Pituitary Adenomas.
    Clin Cancer Res. 2017;23:1841-1851.
    PubMed     Abstract available


    March 2017
  169. LEE H, Shields AF, Siegel BA, Miller KD, et al
    64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.
    Clin Cancer Res. 2017 Mar 15. pii: clincanres.3193.2016.
    PubMed     Abstract available



  170. Correction: PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.
    Clin Cancer Res. 2017;23:1361.
    PubMed    


    February 2017
  171. BLOCH O, Lim M, Sughrue ME, Komotar RJ, et al
    Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy.
    Clin Cancer Res. 2017 Feb 13. pii: clincanres.1369.2016.
    PubMed     Abstract available


    January 2017
  172. RING EK, Markert JM, Gillespie GY, Friedman GK, et al
    Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy.
    Clin Cancer Res. 2017;23:342-350.
    PubMed     Abstract available


    December 2016
  173. HOLDHOFF M, Guner G, Rodriguez FJ, Hicks JL, et al
    Absence of cytomegalovirus in glioblastoma and other high-grade gliomas by real-time PCR, immunohistochemistry and in situ hybridization.
    Clin Cancer Res. 2016 Dec 29. pii: clincanres.1490.2016.
    PubMed     Abstract available


  174. PORTNOW J, Synold TW, Badie B, Tirughana R, et al
    Neural stem cell-based anti-cancer gene therapy: a first-in-human study in recurrent high grade glioma patients.
    Clin Cancer Res. 2016 Dec 15. pii: clincanres.1518.2016.
    PubMed     Abstract available


    November 2016
  175. WANG Z, Hao Y, Zhang CB, Wang Z, et al
    The landscape of viral expression reveals clinically relevant viruses with potential capability of promoting malignancy in lower grade glioma.
    Clin Cancer Res. 2016 Nov 18. pii: clincanres.1495.2016.
    PubMed     Abstract available


  176. DADEY DY, Kapoor V, Hoye K, Khudanyan A, et al
    Antibody targeting GRP78 enhances the efficacy of radiation therapy in human glioblastoma and non-small-cell lung cancer cell lines and tumor models.
    Clin Cancer Res. 2016 Nov 4. pii: clincanres.1935.2016.
    PubMed     Abstract available


    October 2016
  177. ELLIOTT JT, Marra K, Evans LT, Davis SC, et al
    Simultaneous in vivo fluorescent markers for perfusion, protoporphyrin metabolism and EGFR expression for optically guided identification of orthotopic glioma.
    Clin Cancer Res. 2016 Oct 31. pii: clincanres.1400.2016.
    PubMed     Abstract available


  178. KICKINGEREDER P, Gotz M, Muschelli J, Wick A, et al
    Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response.
    Clin Cancer Res. 2016.
    PubMed     Abstract available


  179. STEEG PS, Zimmer AS, Gril B
    Therapeutics for Brain Metastases, Version 3.
    Clin Cancer Res. 2016 Oct 10. pii: clincanres.2035.2016.
    PubMed     Abstract available


    September 2016
  180. RAMACHANDRAN M, Yu D, Dyczynski M, Baskaran S, et al
    Safe and effective treatment of experimental neuroblastoma and glioblastoma using systemically administered triple microRNA-detargeted oncolytic Semliki Forest virus.
    Clin Cancer Res. 2016 Sep 16. pii: clincanres.0925.2016.
    PubMed     Abstract available


  181. POINTER KB, Clark PA, Eliceiri KW, Salamat MS, et al
    Non-torsadogenic human Ether-a-go-go Related Gene (hERG) inhibitors are associated with better survival for high hERG-expressing glioblastoma patients.
    Clin Cancer Res. 2016 Sep 15. pii: clincanres.3169.2016.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: